-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EPwBJxgiEQ/eTPAVK8aS0wT/yIF5XdXdp6xiljZ6xqZxpn6z9Gfrg1YMaIzY/39Q Q3OsvhhRh7aQ6tWy+AGX1w== 0001104659-09-044119.txt : 20090721 0001104659-09-044119.hdr.sgml : 20090721 20090721165640 ACCESSION NUMBER: 0001104659-09-044119 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090721 DATE AS OF CHANGE: 20090721 GROUP MEMBERS: WARBURG PINCUS & CO. GROUP MEMBERS: WARBURG PINCUS LLC GROUP MEMBERS: WARBURG PINCUS PARTNERS, LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SUNESIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81034 FILM NUMBER: 09955513 BUSINESS ADDRESS: STREET 1: 395 OYSTER POINT BOULEVARD STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-3500 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BOULEVARD STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: WARBURG PINCUS EQUITY PARTNERS LP CENTRAL INDEX KEY: 0001075598 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 466 LEXINGTON AVE. CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2128780600 SC 13D/A 1 a09-19302_2sc13da.htm SC 13D/A

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

 

SCHEDULE 13D/A

 

 

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

 

Sunesis Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 Par Value

(Title of Class of Securities)

 

867328 50 2

(CUSIP Number)

 

Scott A. Arenare, Esq.

Managing Director and General Counsel

Warburg Pincus LLC

466 Lexington Avenue

New York, New York  10017

(212) 878-0600

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

With a copy to:

Steven J. Gartner, Esq.

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019

(212) 728-8000

 

July 20, 2009

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

SCHEDULE 13D

 

CUSIP No.   867328 50 2

 

 

1

Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (entities only)

Warburg, Pincus Equity Partners, L.P.

I.R.S. #13-3986317

 

 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x

 

 

3

SEC Use Only

 

 

4

Source of Funds (See Instructions)
N/A

 

 

5

Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
Delaware

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
-0-

 

8

Shared Voting Power
3,445,621**

 

9

Sole Dispositive Power
-0-

 

10

Shared Dispositive Power
3,445,621**

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
3,445,621**

 

 

12

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13

Percent of Class Represented by Amount in Row (11)
9.94%

 

 

14

Type of Reporting Person (See Instructions)
PN

** Includes 241,546 shares of Common Stock issuable upon exercise of the Warrants (with the percentage ownership calculated using the number of outstanding shares of Common Stock after giving effect to the exercise of the Warrants).

 

2


 

SCHEDULE 13D

 

CUSIP No.   867328 50 2

 

 

1

Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (entities only)

Warburg Pincus & Co.

I.R.S. #13-6358475

 

 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x

 

 

3

SEC Use Only

 

 

4

Source of Funds (See Instructions)
N/A

 

 

5

Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
New York

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
-0-

 

8

Shared Voting Power
3,445,621**

 

9

Sole Dispositive Power
-0-

 

10

Shared Dispositive Power
3,445,621**

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
3,445,621**

 

 

12

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13

Percent of Class Represented by Amount in Row (11)
9.94%

 

 

14

Type of Reporting Person (See Instructions)
PN

** Includes 241,546 shares of Common Stock issuable upon exercise of the Warrants (with the percentage ownership calculated using the number of outstanding shares of Common Stock after giving effect to the exercise of the Warrants).

 

3


 

SCHEDULE 13D

 

CUSIP No.   867328 50 2

 

 

1

Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (entities only)

Warburg Pincus LLC

I.R.S. #13-3536050

 

 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x

 

 

3

SEC Use Only

 

 

4

Source of Funds (See Instructions)
N/A

 

 

5

Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
New York

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
-0-

 

8

Shared Voting Power
3,445,621**

 

9

Sole Dispositive Power
-0-

 

10

Shared Dispositive Power
3,445,621**

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
3,445,621**

 

 

12

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13

Percent of Class Represented by Amount in Row (11)
9.94%

 

 

14

Type of Reporting Person (See Instructions)
OO

** Includes 241,546 shares of Common Stock issuable upon exercise of the Warrants (with the percentage ownership calculated using the number of outstanding shares of Common Stock after giving effect to the exercise of the Warrants).

 

4


 

SCHEDULE 13D

 

CUSIP No.   867328 50 2

 

 

1

Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (entities only)

Warburg Pincus Partners, LLC

I.R.S. #13-4069737

 

 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x

 

 

3

SEC Use Only

 

 

4

Source of Funds (See Instructions)
N/A

 

 

5

Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
New York

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
-0-

 

8

Shared Voting Power
3,445,621**

 

9

Sole Dispositive Power
-0-

 

10

Shared Dispositive Power
3,445,621**

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
3,445,621**

 

 

12

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13

Percent of Class Represented by Amount in Row (11)
9.94%

 

 

14

Type of Reporting Person (See Instructions)
OO

** Includes 241,546 shares of Common Stock issuable upon exercise of the Warrants (with the percentage ownership calculated using the number of outstanding shares of Common Stock after giving effect to the exercise of the Warrants).

 

5


 

Introduction.

 

This Amendment No. 4 to the Schedule 13D (this “Amendment”) amends the Schedule 13D filed with the Securities and Exchange Commission on October 6, 2005, as amended by Amendment No. 1 thereto filed with the Securities and Exchange Commission on March 23, 2006, as amended by Amendment No. 2 thereto filed with the Securities and Exchange Commission on May 31, 2007, as further amended by Amendment No. 3 thereto filed with the Securities and Exchange Commission on July 14, 2009 (as so amended, the “Current Schedule 13D”), on behalf of Warburg, Pincus Equity Partners, L.P., a Delaware limited partnership (together with two affiliated entities, “WPEP”), Warburg Pincus LLC, a New York limited liability company (“WP LLC”), Warburg Pincus & Co., a New York general partnership (“WP”), and Warburg Pincus Partners LLC, a New York limited liability company and a subsidiary of WP (“WPP LLC”).  The holdings of Common Stock of WPEP, WP LLC, WP and WPP LLC include certain shares of Common Stock which may be deemed to be beneficially owned by Warburg, Pincus Netherlands Equity Partners I, C.V. (“WPNEP I”) and Warburg, Pincus Netherlands Equity Partners III, C.V. (“WPNEP III” and, together with WPEP and WPNEP I, the “Investors”). The Investors, WP, WP LLC and WPP LLC are collectively referred to as the “Warburg Pincus Reporting Persons.”  This Amendment relates to the common stock, par value $0.0001 per share (the “Common Stock”), of Sunesis Pharamaceuticals, Inc., a Delaware corporation (the “Company”). Charles R. Kaye and Joseph P. Landy are Managing General Partners of WP and Managing Members and Co-Presidents of WP LLC and may be deemed to control the Warburg Pincus Reporting Persons. Messrs. Kaye and Landy disclaim beneficial ownership of all shares held by the Warburg Pincus Reporting Persons.

 

The Warburg Pincus Reporting Persons are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  Each Warburg Pincus Reporting Person disclaims beneficial ownership of all shares of Common Stock to which such Warburg Pincus Reporting Person does not have a pecuniary interest.

 

Unless otherwise indicated herein, each capitalized term used but not otherwise defined herein shall have the meaning ascribed to such term in the Current Schedule 13D.

 

Item 5.

Interest in Securities of the Issuer.

 

Item 5 of the Current Schedule 13D is hereby amended and replaced in its entirety as set forth below.

 

(a)           From July 14, 2009 through July 21, 2009, WPEP sold an aggregate of 750,000 shares of the Common Stock in open market transactions for aggregate proceeds of approximately $217,916.  Immediately following the completion of the sales on July 21, 2009, each of the Warburg Pincus Reporting Persons may be deemed to beneficially own 3,445,621 shares of the Common Stock, representing 9.94% of the outstanding Common Stock,

 

6


 

based on the 34,409,768 shares of Common Stock outstanding as of April 30, 2009 as reported by the Company in its Form 10-Q filed on May 8, 2009, and 241,546 shares of Common Stock issuable upon exercise of the Warrants.

 

(b)           Each of the Warburg Pincus Reporting Persons shares the power to vote or to direct the vote and to dispose or to direct the disposition of the 3,445,621 shares of Common Stock it may be deemed to beneficially own.  The Warburg Pincus Reporting Persons are making this single, joint filing within the meaning of Section 13(d)(3) of the Exchange Act. The filing of this Amendment shall not be construed as an admission of such beneficial ownership or that the Warburg Pincus Reporting Persons constitute a person or group.

 

(c)           Schedule I hereto sets forth a list of all transactions with respect to the shares of the Common Stock effected by any of the Warburg Pincus Reporting Persons since July 14, 2009, inclusive of any transactions effected through 5:30 p.m., Eastern Standard Time, on July 21, 2009.  All such transactions were effected in the open market.  A list of transactions that were effected during the past sixty days and prior to July 14, 2009 is attached as Schedule I to Amendment No. 3 to the Schedule 13D, which was filed with the Securities and Exchange Commission on July 14, 2009.

 

(d)           Not applicable.

 

(e)           Not applicable.

 

7


 

SIGNATURES

 

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated: July 21, 2009

WARBURG, PINCUS EQUITY PARTNERS, L.P.

 

 

By: Warburg Pincus Partners, LLC,

 

 

its General Partner

 

 

 

 

 

By: Warburg Pincus & Co., its Managing Member

 

 

 

By:

/s/ Scott A. Arenare

 

 

Name:  Scott A. Arenare

 

 

Title:    Partner

 

 

Dated: July 21, 2009

WARBURG PINCUS & CO.

 

 

 

 

 

By:

/s/ Scott A. Arenare

 

 

Name:  Scott A. Arenare

 

 

Title:    Partner

 

 

 

 

 

Dated: July 21, 2009

 

 

WARBURG PINCUS LLC

 

 

 

 

 

By:

/s/ Scott A. Arenare

 

 

Name:  Scott A. Arenare

 

 

Title:    Managing Director

 

 

Dated: July 21, 2009

WARBURG PINCUS PARTNERS, LLC

 

 

By: Warburg Pincus & Co., its Managing Member

 

 

 

By:

/s/ Scott A. Arenare

 

 

Name:  Scott A. Arenare

 

 

Title:    Partner

 

8


SCHEDULE I

 

Set forth below is a list of all transactions with respect to the shares of the common stock, par value $0.0001 per share, of Sunesis Pharmaceuticals, Inc., effected by any of the Warburg Pincus Reporting Persons (as defined in the Amendment No. 4 to the Schedule 13D to which this Schedule I is attached) since July 14, 2009, inclusive of any transactions effected through 5:30 p.m., Eastern Standard Time, on July 21, 2009.  All such transactions were effected in the open market.

 

Date

 

Selling Entity

 

Number of Shares

 

Per Share Price ($)

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

25,200

 

0.3150

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

50,975

 

0.3200

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

2,900

 

0.3202

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3204

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

10,225

 

0.3205

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

300

 

0.3216

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3241

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

400

 

0.3247

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3257

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3270

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

25

 

0.3280

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3295

 

 


 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

14,275

 

0.3300

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,700

 

0.3301

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3303

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3304

 

7/14/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3347

 

7/15/09

 

Warburg, Pincus Equity Partners, L.P.

 

41,770

 

0.3200

 

7/15/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3215

 

7/15/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3250

 

7/15/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3251

 

7/15/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3252

 

7/15/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3287

 

7/15/09

 

Warburg, Pincus Equity Partners, L.P.

 

150

 

0.3300

 

7/15/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3326

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

39,000

 

0.3000

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3003

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3005

 

 

2


 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

500

 

0.3010

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

300

 

0.3011

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3015

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

300

 

0.3016

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

44,700

 

0.3018

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3019

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

400

 

0.3020

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

2,400

 

0.3022

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

900

 

0.3023

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

43,800

 

0.3100

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

300

 

0.3101

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.3102

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3150

 

7/16/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,000

 

0.3200

 

7/17/09

 

Warburg, Pincus Equity Partners, L.P.

 

5,600

 

0.3000

 

7/17/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.3099

 

 

3


 

7/17/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,925

 

0.3100

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

91,427

 

0.2800

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

800

 

0.2801

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

2,200

 

0.2802

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

300

 

0.2803

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

700

 

0.2804

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.2805

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,100

 

0.2806

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

800

 

0.2807

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.2808

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

400

 

0.2810

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,300

 

0.2811

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.2812

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

300

 

0.2815

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.2820

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,000

 

0.2822

 

 

4


 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.2823

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,813

 

0.2825

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,400

 

0.2835

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

600

 

0.2851

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

60

 

0.2852

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

4,600

 

0.2900

 

7/20/09

 

Warburg, Pincus Equity Partners, L.P.

 

600

 

0.2901

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

127,581

 

0.2700

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

700

 

0.2701

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,800

 

0.2702

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

3,200

 

0.2708

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

300

 

0.2716

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,000

 

0.2717

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

35,400

 

0.2720

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

2,000

 

0.2721

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

700

 

0.2722

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

200

 

0.2723

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

7,000

 

0.2730

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

9,000

 

0.2750

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

39,800

 

0.2798

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

5,000

 

0.2799

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

96,374

 

0.2800

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.2801

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.2802

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

2,100

 

0.2804

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

400

 

0.2805

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

800

 

0.2830

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

3,000

 

0.2848

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

4,500

 

0.2850

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

100

 

0.2900

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

1,100

 

0.2910

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

5,000

 

0.2930

 

7/21/09

 

Warburg, Pincus Equity Partners, L.P.

 

400

 

0.2931

 

 

5

 -----END PRIVACY-ENHANCED MESSAGE-----